4//SEC Filing
Pizzuti Dana 4
Accession 0001628280-25-055054
CIK 0001658247other
Filed
Dec 2, 7:00 PM ET
Accepted
Dec 3, 4:28 PM ET
Size
9.1 KB
Accession
0001628280-25-055054
Insider Transaction Report
Form 4
Pizzuti Dana
Chief Med and Dev Officer
Transactions
- Exercise/Conversion
Common Stock
2025-12-01$16.89/sh+5,000$84,450→ 71,837 total - Sale
Common Stock
2025-12-01$45.02/sh−5,000$225,100→ 66,837 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-12-01−5,000→ 69,042 totalExercise: $16.89Exp: 2032-10-10→ Common Stock (5,000 underlying)
Footnotes (4)
- [F1]Includes 567 shares acquired under the Issuer's Employee Stock Purchase Plan.
- [F2]The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 21, 2025.
- [F3]The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sale price of $45.02 per share. The range of sale prices on the transaction date was $44.59 to $45.51. Detailed information on the exact number of shares can be obtained from the Issuer upon request.
- [F4]The option is exercisable as follows: 25% of the shares subject to the option vested on September 30, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.
Documents
Issuer
Crinetics Pharmaceuticals, Inc.
CIK 0001658247
Entity typeother
Related Parties
1- filerCIK 0001948238
Filing Metadata
- Form type
- 4
- Filed
- Dec 2, 7:00 PM ET
- Accepted
- Dec 3, 4:28 PM ET
- Size
- 9.1 KB